GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Repare Therapeutics Inc (NAS:RPTX) » Definitions » Beneish M-Score

Repare Therapeutics (Repare Therapeutics) Beneish M-Score : 7.58 (As of May. 03, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Repare Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 7.58 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Repare Therapeutics's Beneish M-Score or its related term are showing as below:

RPTX' s Beneish M-Score Range Over the Past 10 Years
Min: 7.58   Med: 10.29   Max: 45.71
Current: 7.58

During the past 7 years, the highest Beneish M-Score of Repare Therapeutics was 45.71. The lowest was 7.58. And the median was 10.29.


Repare Therapeutics Beneish M-Score Historical Data

The historical data trend for Repare Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repare Therapeutics Beneish M-Score Chart

Repare Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - 45.71 10.29 7.58

Repare Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.29 10.40 13.55 -1.20 7.58

Competitive Comparison of Repare Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Repare Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repare Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Repare Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Repare Therapeutics's Beneish M-Score falls into.



Repare Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Repare Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 9.1319+0.528 * 1+0.404 * 7.7099+0.892 * 0.3879+0.115 * 0.8312
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 2.6735+4.679 * 0.132536-0.327 * 0.7021
=7.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $15.31 Mil.
Revenue was 13.047 + 2.159 + 30.249 + 5.678 = $51.13 Mil.
Gross Profit was 13.047 + 2.159 + 30.249 + 5.678 = $51.13 Mil.
Total Current Assets was $243.69 Mil.
Total Assets was $253.90 Mil.
Property, Plant and Equipment(Net PPE) was $7.54 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.95 Mil.
Selling, General, & Admin. Expense(SGA) was $33.76 Mil.
Total Current Liabilities was $39.08 Mil.
Long-Term Debt & Capital Lease Obligation was $1.01 Mil.
Net Income was -28.03 + -18.879 + -11.946 + -34.941 = $-93.80 Mil.
Non Operating Income was -0.079 + -0.072 + -0.067 + -0.071 = $-0.29 Mil.
Cash Flow from Operations was -28.156 + -32.87 + -34.346 + -31.786 = $-127.16 Mil.
Total Receivables was $4.32 Mil.
Revenue was 18.198 + 112.545 + 0.679 + 0.408 = $131.83 Mil.
Gross Profit was 18.198 + 112.545 + 0.679 + 0.408 = $131.83 Mil.
Total Current Assets was $353.98 Mil.
Total Assets was $364.08 Mil.
Property, Plant and Equipment(Net PPE) was $9.60 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.98 Mil.
Selling, General, & Admin. Expense(SGA) was $32.56 Mil.
Total Current Liabilities was $78.62 Mil.
Long-Term Debt & Capital Lease Obligation was $3.26 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(15.312 / 51.133) / (4.323 / 131.83)
=0.299454 / 0.032792
=9.1319

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(131.83 / 131.83) / (51.133 / 51.133)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (243.688 + 7.541) / 253.901) / (1 - (353.979 + 9.599) / 364.075)
=0.010524 / 0.001365
=7.7099

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=51.133 / 131.83
=0.3879

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.978 / (1.978 + 9.599)) / (1.951 / (1.951 + 7.541))
=0.170856 / 0.205542
=0.8312

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(33.764 / 51.133) / (32.56 / 131.83)
=0.660317 / 0.246985
=2.6735

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.01 + 39.079) / 253.901) / ((3.257 + 78.619) / 364.075)
=0.157892 / 0.224888
=0.7021

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-93.796 - -0.289 - -127.158) / 253.901
=0.132536

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Repare Therapeutics has a M-score of 7.58 signals that the company is likely to be a manipulator.


Repare Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Repare Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Repare Therapeutics (Repare Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7210 Frederick-Banting Street, Suite 100, Saint-Laurent, QC, CAN, H4S 2A1
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
Executives
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Michael Zinda officer: EVP, Chief Science Officer C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Susan Molineaux director C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Davis Jerel director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures V, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage I, L.p. 10 percent owner ONE SANSOME, SUITE 1650, SAN FRANCISCO CA 94104
Thomas Civik director C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104

Repare Therapeutics (Repare Therapeutics) Headlines

From GuruFocus

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

By Business Wire Business Wire 02-02-2023

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

By Business Wire Business Wire 11-07-2022